Short answer
IDEAYA Biosciences, Inc. (IDYA) filed an 8-K current report with the SEC on April 13, 2026 reporting Item 8.01 (Other Events). OptimUM-02 met its primary endpoint, reducing progression risk 58% versus investigator-choice therapy.
IDEAYA Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- OptimUM-02 met its primary endpoint, reducing progression risk 58% versus investigator-choice therapy
- Median PFS improved to 6.9 months from 3.1 months, with hazard ratio 0.42 and p-value <0.0001
- ORR reached 37.1% versus 5.8%; five complete responses versus none in the control arm
- NDA submission targeted for the second half of 2026, creating a key regulatory catalyst
- Overall survival remains immature; Grade 3+ adverse events included diarrhea, syncope, and hypotension
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IDEAYA Biosciences, Inc. 8-K filings
Get the next IDYA 8-K as it lands
Follow IDYA for push alerts, or ask the research agent what this filing means.